Evofem Biosciences, Inc., (NASDAQ: EVFM)is developing and commercializing innovative products to address unmet needs in women’s sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company launched its first FDA-approved commercial product, Phexxi® (lactic acid, citric acid and potassium bitartrate), in the U.S. in September 2020. It plans to commercialize Phexxi in foreign markets through partnerships. Top line results are expected in Q2 2022 from the pivotal Phase 3 clinical trial evaluating Evofem’s lead product candidate, EVO100, for the prevention of urogenital chlamydiaandgonorrheainfections in women. For more information, please visit www.evofem.com and www.phexxi.com.
To register for LD Micro’s Invitational XI and watch the live presentation, visit https://ibn.fm/InvitationalXIRegistration
To view IBN’s virtual coverage of the investor conference, visit https://ibn.fm/InvitationalXI
About InvestorBrandNetwork’s Virtual Coverage
The InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, is providing the online investment community with a custom-built portal that includes summaries on each of the publicly traded companies participating virtually at LD Micro’s 11th Annual Invitational. In addition to enabling proficient evaluation of each company via one-click access to market research tools and helpful website links, IBN is using social media and syndicated articles to maximize the visibility of the event.
For more than a decade, IBN has provided real-time coverage for numerous global events and conferences through its various brands, social media accounts and investment newsletters. To further expand visibility of participating companies at these events, and to ensure another successful year for its event collaborations, IBN’s syndication partners have extended digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com
